Other languages Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Real-time Estimate Cboe BZX Other stock markets 02:50:49 2024-05-09 pm EDT			5-day change	1st Jan Change
139.9 ^USD	+0.62%		+0.01%	+6.13%

May. 08	Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	CI
May. 07	Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst? Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	May. 08
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst? Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024	May. 07
Neurocrine Biosciences Presents CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024	May. 03
Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell	May. 01
Neurocrine Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01
Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024	May. 01
Neurocrine Gets FDA Approval for Ingrezza Sprinkle Capsules; Shares Rise After-Hours	Apr. 30
Neurocrine Biosciences' Huntington's disease drug gets FDA approval	Apr. 30
FDA approves Neurocrine Biosciences' Huntington's disease drug	Apr. 30
Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules	Apr. 30
Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community	Apr. 24
Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder	Apr. 23
Sentia Medical Sciences Inc. and Neurocrine Biosciences, Inc. Extend Research Collaboration to Discover Novel CRF Peptides	Apr. 16
Neurocrine Biosciences Doses First Patient in Phase 2 Depressive Disorder Study	Apr. 03
Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder	Apr. 03
Neurocrine Biosciences Starts Phase 1 Trial of Investigational Neuropsychiatric Drug	Mar. 28
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults	Mar. 28
Neurocrine Biosciences Insider Sold Shares Worth $5,576,710, According to a Recent SEC Filing	Mar. 15
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing	Mar. 15
Neurocrine Biosciences Insider Sold Shares Worth $922,632, According to a Recent SEC Filing	Mar. 01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Other languages

Filters